Chiron ( CHIR) said Thursday that the Food and Drug Administration approved its Procleix blood testing system for early detection of a type of HIV and hepatitis C.

Approval of Procleix was expected at the end of last year, but some quality control issues caused a delay. It could have been worse -- some analysts and blood-banking officials had predicted a delay of up to six months.

Procleix, also known as the nucleic acid amplification test, is a super-sensitive screening method that detects at a very early stage the presence of Type 1 HIV and Hepatitis C viruses in donated blood. The system detects these viruses before they would be picked up by other blood-screening methods.

Procleix is already used to screen about 70% of the U.S. blood donations, but until FDA approval, Chiron was only allowed to sell the test at cost.

Chiron was up $1.59, or almost 4%, to $43.22 per share, in recent trading.

If you liked this article you might like

Goodbye

Goodbye

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio